GFR decline as an end point in trials of CKD: a viewpoint from the FDA
- PMID: 25446026
- DOI: 10.1053/j.ajkd.2014.09.006
GFR decline as an end point in trials of CKD: a viewpoint from the FDA
Comment on
-
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.Am J Kidney Dis. 2014 Dec;64(6):821-35. doi: 10.1053/j.ajkd.2014.07.030. Epub 2014 Oct 16. Am J Kidney Dis. 2014. PMID: 25441437 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical